在神经系统疾病中基于外体调节铁亡:机制,治疗潜力和转化挑战
Xiaoying Bao1, Liwei Chen1, Hong Yu1
1Geriatrics Center, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
Frontiers in immunology
|November 5, 2025
概括
铁亡,细胞死亡途径,驱动神经系统疾病. 外体细胞在准这种神经保护途径方面表现有前途,为大脑疾病提供潜在的新疗法.
科学领域:
- 神经科学是一个神经科学.
- 细胞生物学 细胞生物学
- 生物化学 生化学
背景情况:
- 诸如中风,阿尔茨海默氏症和帕金森氏症等神经系统疾病是全球健康面临的重大挑战.
- 铁,一种涉及铁和脂质过氧化的受调细胞死亡形式,是这些条件中的关键病理机制.
研究的目的:
- 审查神经疾病中铁亡的机制.
- 突出外体在调节铁亡的治疗潜力,以进行神经保护.
主要方法:
- 文献综述综合了关于铁和外体的当前研究.
- 对外体载荷的分析及其对铁体路径的影响 (例如,GPX4-GSH轴,铁稳定性).
主要成果:
- 外体细胞可以穿越血脑屏障并提供治疗分子.
- 在各种神经损伤模型中,铁亡途径的外体介导调节显示了神经保护作用.
结论:
- 外体代表了一个有前途的精确交付平台,用于针对神经疾病中的铁亡.
- 需要进一步的研究和临床转化,以确定外体导向神经保护作为一个可行的治疗策略.
相关概念视频
Overview of Exosomes
3.5K
Exosomes are stable, lipid bilayer-enclosed vesicles capable of crossing biological barriers. They can carry a wide range of molecules required for intercellular communication. Once exosomes are released from the cell where they originated, they enter a recipient cell through various pathways such as fusion, receptor-mediated endocytosis, macropinocytosis, and phagocytosis.
Stahl et al. discovered exosomes in 1983, but the exosomes were initially considered waste products released from the...
Stahl et al. discovered exosomes in 1983, but the exosomes were initially considered waste products released from the...
3.5K
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
804
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
804

